Staar SurgicalStaar Surgical (NSDQ:STAA) shares ticked up today on second-quarter results that topped the consensus forecast.

The Lake Forest, Calif.-based implantable lens maker posted profits of $8.6 million, or 17¢ per share, on sales of $62.4 million for the three months ended July 2, 2021, for a massive bottom-line from over $1 million in the red this time last year on sales growth of 77.2%.

Adjusted to exclude one-time items, earnings per share were 27¢, 3¢ ahead of Wall Street, where analysts were looking for sales of $52.6 million.

“STAAR’s second-quarter results reflect the accelerating sales momentum and significant opportunity for our vision correction lenses,” Staar Surgical president & CEO Caren Mason said in a news release. “Global ICL unit growth increased 79% over the prior-year quarter and we achieved positive sales and unit growth in all of our major markets. Asia, Europe, and the U.S. led our outperformance during the quarter. The Middle East, North Africa, and India, even harder hit by the pandemic than most of our developed major markets in 2020, rebounded strongly.”

“Following our achievement of record-breaking first half 2021 results and with increasing visibility into key second-half growth drivers for our business, we are today raising our outlook for full-year fiscal 2021 net sales to a range of $227 million to $230 million, up from our previously provided outlook of $215 million to $217 million that we shared on May 5th. At the mid-point, our increased sales outlook for the fiscal year 2021 represents approximately 40% growth year over year.”

Staar Surgical raised its sales guidance for the full year, increasing the previous projection of a range of $215 million to $217 million to an estimate of revenues between $227 million and $230 million.

STAA shares were up 4.3% at $146.07 per share in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down -0.9%.